Why the study?
Does sacubitril/valsartan reduce morbidity and mortality in patients with heart failure compared to standard ACE inhibitor therapy?
Does sacubitril/valsartan reduce morbidity and mortality in patients with heart failure compared to standard ACE inhibitor therapy?
Answers are grounded in this paper and cite their sources.
Sacubitril/valsartan offers a novel and effective therapeutic approach for heart failure by simultaneously blocking neprilysin and angiotensin II receptors.
The novel combination sacubitril/valsartan represents a new therapeutic approach in the management of heart failure. With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while avoiding the deleterious effect of angiotensin II receptors activation and thereby encompasses a beneficial impact of 2 important neurohormonal pathways activated in heart failure. As opposed to previously tested neprilysin inhibitors, sacubitril/valsartan represents a more effective method in reducing morbidity and mortality in heart failure, while preserving a safety profile comparable to well-established, standard, angiotensin-converting enzyme inhibitor's therapy.
No takes yet. Share an insight, caveat, or question.
Havakuk et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: